Tirzepatide 5mg KwikPen
Product Overview
| Generic Name | Tirzepatide 5mg KwikPen |
| Brand Name(s) | Mounjaro, Zepbound |
| Category | Antidiabetic Agents |
| Form | 5mg KwikPen, 4/week multi-dose prefilled syringe pen |
| Strength | 5 mg. / 0.5 mL, |
| Therapeutic Class | Dual GIP–GLP-1 receptor agonist for T2DM, obesity, and sleep apnea |
| ATC Code | A10BK04 |
Manufacturing & Regulatory
| Manufacturer | Eli Lilly; API also sourced from Indian CDMOs |
| GMP Compliance | WHO-GMP, API mfgs hold ISO/FDA certificates |
| DMF/CEP | DMFs via API suppliers (Type II) |
| COFEPRIS | Under Registration (2025) |
| Free Sale Certificate | Yes |
Logistics & Export
| MOQ | 10 units |
| Shelf Life | 24 Months |
| Storage | Refrigerated (2–8 °C) |
| Incoterms | FOB / CIF / DDP |
| Lead Time | 7 - 10 Business Days |
Documentation Available Upon Request
| Certificate of Analysis (PDF) | Yes |
| SDS-Safety Data Sheet (PDF) | Upon Request |
| CTD Summary (PDF) | CTD from originator; generic use abbreviated formats |
Special Notes
A dual agonist of the GLP‑1 and glucose‑dependent insulinotropic polypeptide (GIP) receptors; simultaneous stimulation of both receptors synergistically amplifies insulinotropic effects, augments adipose‑tissue lipolysis, and further attenuates hunger signals, resulting in superior weight loss of up to 20 % of baseline body weight, surpassing the efficacy of selective GLP‑1 agonism.
Once-weekly injection for type 2 diabetes obesity management. Demonstrates marked reductions in HbA1c and weight (~15–20%) with favorable safety profile.